46th week of 2014 patent applcation highlights part 48 |
Patent application number | Title | Published |
20140336081 | BIOCHIP SUBSTRATUM AND METHOD FOR PRODUCTION THEREOF - A substrate for biochips which has a high probe loading amounts and a uniform immobilization density, and which further has a high detection sensitivity and a high reproducibility by preventing a non-specific adsorption of proteins, when used as a substrate for biochips for immobilizing probes composed of biologically relevant substances such as proteins and nucleic acids, is disclosed. Amino groups can be bound to the surface of the substrate uniformly, at a high density and stably by covalently immobilizing an amino group-containing polymer on the surface of the substrate. The probe immobilization rate is high and immobilizing density was uniform by immobilizing a probe composed of a biologically relevant substance such as a protein or nucleic acid by utilizing the amino groups. Further, detection sensitivity and reproducibility are high by inhibiting non-specific adsorption of proteins. | 2014-11-13 |
20140336083 | SYSTEM FOR PORTABLE AND EASY-TO-USE DETECTION OF ANALYTES WITH MOBILE COMPUTING DEVICE - This system takes in raw cellular material collected using a provided swab, blood collection device, urine collection device, or other sample collection device and transforms that biological material into a digital result, identifying the presence, absence and/or quantity of nucleic acids, proteins, and/or other molecules of interest. | 2014-11-13 |
20140336084 | COATED SUBSTRATES FOR HIGH ENERGY CAPTURE PHASE BINDING AND METHODS OF PRODUCTION AND USE THEREOF - A substrate, which is useful for performing biological, chemical and diagnostic assays, and a method for preparing the substrate are provided. The substrate has an upper surface with a coating disposed thereon. The coating comprises a charged polymer, a non-ionic polyether, and a silicate compound. The substrate can increase capture phase binding and reduce non-specific binding of biomolecules for a biological microarray. | 2014-11-13 |
20140336085 | Additives for Oil-Based Drilling Fluids - An additive for a wellbore treatment fluid comprising a sulfonated asphalt compound comprising particles having a D90 particle size of less than about 215 μm. A wellbore treatment fluid comprising (i) an oleaginous component and (ii) a sulfonated asphalt wherein the sulfonated asphalt comprises particles having a D90 of less than about 215 μm. | 2014-11-13 |
20140336086 | VISCOSIFIERS FOR DRILLING FLUIDS - A drilling fluid comprising 0.1 to 50% by weight of at least one viscosifier selected from epoxidized fatty acid esters, wherein the fatty acid of the fatty acid ester is derived from natural oils or animal fats, and the fatty acid is substantially fully esterified with monohydric or polyhydric alcohols or mixtures thereof. | 2014-11-13 |
20140336087 | DRILLING SOLUTIONS AND METHODS - A drilling fluid for discharging in a borehole to facilitate drilling operations, and hydraulic fracturing in particular, comprising amorphous silicas having a particle size ranging from about one to about ten nanometers and water, wherein the pH of the fluid is substantially neutral. | 2014-11-13 |
20140336088 | LIQUEFIED POLYMER FRACTURING FLUID THICKENER AND PREPARATION METHOD THEREOF - The present invention relates to a liquefied polymer fracturing fluid thickener, which has evaluation indexes as: a density of 1.0-1.3 g/cm | 2014-11-13 |
20140336089 | Scale Inhibitor - This invention relates to a process for inhibiting scaling in a subterranean oil or gas producing formation, comprising adding to the formation a composition comprising a metal chelant, a scale inhibitor and divalent metal cations, wherein the stability constant of the metal chelant—metal cation chelate at ambient temperature is equal to or higher than the stability constant of the chelate formed from the metal cations and the scale inhibitor, and wherein the solubility of the chelate formed from the metal cations and the scale inhibitor decreases with increasing temperature. | 2014-11-13 |
20140336090 | GREASE COMPOSITION AND BEARING - The invention provides a grease composition which contains (a) a base oil, (b) a thickener, (c) a compound having an alkylthiocarbamoyl group, represented by the formula (1), (d) a hindered phenol antioxidant, and (e) a metal deactivator; | 2014-11-13 |
20140336091 | USE OF O/W EMULSIONS FOR CHAIN LUBRICATION - The invention relates to the use of an O/W emulsion, in particular a PIT emulsion, for lubricating conveyor belt systems in food industries as well as a lubricant concentrate based on an O/W emulsion, in particular a PIT emulsion, of wax esters. | 2014-11-13 |
20140336092 | SEAL SWELL ADDITIVE - A seal swell agent for a lubricating fluid is described. The invention relates to a seal swell agent for use in lubricating oils, such as engine oils, turbine oils, automatic and manual transmission, or gear, fluids, drivetrain and gear oils and hydraulic fluids. The seal swell agent comprises a diester of sorbitol or a derivative thereof and at least one carboxylic acid. The invention extends to the use of a diester of sorbitol or a derivative thereof and at least one carboxylic acid as a seal swell agent, and a method of maintaining seal integrity. | 2014-11-13 |
20140336093 | SILICONE SOLVENT - Cured or uncured silicones are effectively removed from substrates with minimized substrate corrosion by the use of a silicone dissolver containing a tetralkylammonium fluoride and an inorganic base, dissolved in a solvent. | 2014-11-13 |
20140336094 | CLEANING COMPOSITION AND METHOD OF FORMING THE SAME - A cleaning composition, useful for dishwashing, comprises about 1 to about 35 weight percent (wt. %) of an anionic surfactant, about 1 to about 35 wt. % of a nonionic surfactant, and at least about 1 wt. % of lactic acid. The anionic and nonionic surfactants are present in a combined amount of at least about 8 wt. %. Each of the weight percentages is based on 100 parts by weight of the composition. The composition has a pH of no greater than about 4. A method of forming the composition comprises the steps of combining the anionic and nonionic surfactants to form a first solution, and combining a supplemental acid different from lactic acid with the first solution to form a second solution. The second solution has a pH of no greater than about 5. The method further comprises the step of combining the lactic acid and second solution to form the composition. | 2014-11-13 |
20140336095 | SOLID SURFACTANT COMPOSITION - A surfactant product is in the form of a solid. The surfactant product includes (i) sodium carbonate; (ii) cream of tartar; (iii) glycerine; (iv) sodium lauryl sulphate in an amount of from 3 to 15 wt % based on the weight of the total composition, and (v) sodium laureth sulphate in an amount of from 10 to 25 wt % based on the weight of the total composition. | 2014-11-13 |
20140336096 | LAUNDRY STAIN AND SOIL PRETREATMENT DEVICES - A laundry stain and soil pretreatment sheet including a water soluble or water dispersible carrier layer, preferably polyvinyl alcohol, a removable separator layer, and a layer of cleaning agent composition therebetween. The separator layer is removed, the composition layer is adhered to a stain on clothing, and the clothing is laundered. The carrier layer dissolves or disperses during the laundering. The separator layer can be water soluble or water dispersible. Depressions can be provided in the carrier layer to hold the layer of cleaning agent composition. Without the separator layer, a sheet of the carrier layer can be folded over to hold the cleaning agent composition. | 2014-11-13 |
20140336097 | DETERGENT COMPOSITION COMPRISING ALKALI METAL HYDROXIDE AND METHODS OF MODIFYING A SURFACE - An alkaline detergent is described which includes the use of polycarboxylic acid copolymers or salts thereof in combination with alkali metal hydroxide. The detergent composition reduces spotting and filming and prevents hard water scale accumulation between 145-180 degrees Fahrenheit and with a pH of 10.5 to about 13. | 2014-11-13 |
20140336098 | Stabilized Subtilisin Composition - The conversion of a peptide aldehyde to a hydrosulfite adduct can be used to increase the aqueous solubility in the purification of the peptide aldehydes. Advantageously, this hydrosulfite adduct is itself effective as a subtilisin inhibitor and stabilizer and it can also stabilize a second enzyme if present. The hydrosulfite adduct is effective as a subtilisin inhibitor, and it maintains its inhibitory and stabilizing effect in a liquid detergent during storage. Thus, use of the hydrosulfite adduct can avoid the cost and time of converting it back to the peptide aldehyde and subsequent drying of the peptide aldehyde can be saved, and this can avoid the inconvenience of handling the peptide aldehyde in powder form or as a highly diluted aqueous solution. | 2014-11-13 |
20140336099 | DETERGENT COMPOSITION INCLUDING A SACCHARIDE OR SUGAR ALCOHOL - Solid detergent compositions according to the present invention include at least one alkali metal silicate, at least one polycarboxylic acid, at least one saccharide or sugar alcohol and water. Suitable saccharides include sucrose, fructose, inulin, maltose and lactulose, and may be present in the composition in a concentration of at least 0.5 wt %. Compositions according to certain embodiments form stable solid block detergent compositions that do not swell significantly even when subjected to elevated temperatures. | 2014-11-13 |
20140336100 | Modified Lipids Produced from Oil-Bearing Microbial Biomass and Oils - Chemically modified lipids and methods for their preparation are provided. | 2014-11-13 |
20140336101 | NOVEL THICKENING POLYMER - Polymer obtainable by radical emulsion polymerization of (A) at least one acidic vinyl monomer or salt thereof; (B) at least one nonionic vinyl monomer, particularly preferably a hydrophobic nonionic vinyl monomer; (C) at least one monomer containing an unsaturated end group and a polyoxyalkylene part; (D) at least one crosslinking monomer; and (E) optionally, a protective colloid, characterized in that the polymerization is controlled such that (F) the gel effect occurs, at least at times, achieved by adding monomers of type (A), (B), and (C) (dosing time) during 120 minutes; and such that (G) the crosslinking monomer (D) is added, at the very earliest, 10 minutes after the first addition of the monomers (A), (B), and (C). | 2014-11-13 |
20140336102 | NOVEL DIETHYL-METHYL-HEXAHYDRO-ISOBENZOFURANS AND THEIR USE IN PERFUME COMPOSITIONS - The present invention is directed to novel diethyl-methyl-hexahydro-isobenzofuran compounds and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of these novel compounds. | 2014-11-13 |
20140336103 | NOVEL 3,3-DIETHYL-ALKYL-2-OXA-SPIRO[4.5]DEC-7-ENES AND THEIR USE IN PERFUME COMPOSITIONS - The present invention is directed to novel 3,3-diethyl-alkyl-2-oxa-spiro[4.5]dec-7-ene compounds and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of these novel compounds. | 2014-11-13 |
20140336104 | ACTH PROPHYLACTIC TREATMENT OF RENAL DISORDERS - Provided herein are methods for prophylactic treatment of renal disorders comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing a renal disorder | 2014-11-13 |
20140336105 | Anti-Inflammatory Peptides And Use Thereof - Anti-inflammatory peptides and pharmaceutical compositions including lysine, alanine, leucine and/or valine for treating inflammatory conditions and uses thereof. Anti-inflammatory peptides for treating IgE-mediated allergies and inflammatory conditions caused by a microbial infection including but not limited to sepsis. | 2014-11-13 |
20140336106 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS - Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): | 2014-11-13 |
20140336107 | GLP-1 RECEPTOR AGONIST PEPTIDE GASTRIN CONJUGATES - The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders. | 2014-11-13 |
20140336108 | COMPOUNDS AS TYROSINE KINASE MODULATORS - The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors. | 2014-11-13 |
20140336109 | MODULATION OF GHRELIN LEVELS AND GHRELIN/UNACYLATED GHRELIN RATIO USING UNACYLATED GHRELIN - A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject wherein a reduction in ghrelin levels and/or a reduction in ghrelin/unacylated ghrelin ratio is beneficial to the subject. Also, use of ghrelin level and/or ghrelin/unacylated ghrelin ratio as biomarkers for determining a subject's likelihood of responding to and/or benefiting from administration of unacylated ghrelin. | 2014-11-13 |
20140336110 | Modified Mini-Hepcidin Peptides and Methods of Using Thereof - Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof. | 2014-11-13 |
20140336111 | Therapeutic Use of Activators of Zinc Finger Protein GL13 - The present invention relates to the therapeutic use of activators of the zinc finger protein GLI3 in diseases that are associated with reduced Hedgehog signaling in hepatocytes, in particular Polycystic ovary syndrome, Steatosis hepatis, Steatohepatit is and/or Adipositas. The invention further relates to methods of treating an individual with said activator, a pharmaceutical composition comprising said activator and the use of said activator as food supplement. | 2014-11-13 |
20140336112 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 2014-11-13 |
20140336113 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HYPERLIPIDEMIA, FATTY LIVER, ATHEROSCLEROSIS AND OTHER DISORDERS ASSOCIATED WITH METABOLIC SYNDROME - The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject. Compositions and methods including a Nuclear Transport Modifier may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease in cholesterol and triglyceride levels in the blood and liver, a decrease in atherosclerotic lesion size, a decrease in body weight and in hyperglycemia, a reduction of fatty liver inflammation, and an improvement in liver function. | 2014-11-13 |
20140336114 | Buffers for Controlling the pH of Bone Morphogenetic Proteins - The present invention provides formulations of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins that are pH stabilized. In particular, the present invention relates to the observation that certain buffers enhance the stability of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins. In particular, disclosed herein are liquid and lyophilized formulations prepared with a glycylglycine and tartaric acid buffers to stabilize the pH of the formulation. | 2014-11-13 |
20140336115 | Compounds, Compositions and Methods for the Treatment of Diseases Through Inhibiting TGF- Activity - The present disclosure relates to compounds, compositions and methods for the treatment of diseases through inhibiting the activity of the transforming growth factor beta (TGF-β). More specifically, the disclosed compounds, compositions and methods are useful in the treatment of certain cancers (e.g. multiple myeloma, hematologic malignancies), diseases associated with excessive TGF-β activity including fibrosis, dermal scarring, immune dysfunction, and bone loss by inhibiting the conversion of latent TGF-β to active TGF-β. A method of preventing the activation of TGF-β in pathology is also provided, comprising administering an amount of the compounds sufficient to inhibit conversion of latent TGF-β to active TGF-β by thrombospondinl (TSP1), resulting in reduced TGF-β activity and reduced adverse effects such as fibrosis, bone loss, and immune dysfunction. | 2014-11-13 |
20140336116 | Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide - [Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analog thereof being replaced with a glycosylated amino acid. | 2014-11-13 |
20140336117 | MODIFIED RECEPTOR FUSION PROTEINS - We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists. | 2014-11-13 |
20140336118 | POLYPEPTIDE FOR THE PROTECTION AGAINST HEART ISCHEMIA-REPERFUSION INJURY - A peptide of the formula R | 2014-11-13 |
20140336119 | POLYPEPTIDES TARGETING GLYCOSYLATED MUC2 PROTEINS, METHODS OF SYNTHESIS, THEIR NUCLEIC ACIDS AND USES THEREOF - The invention relates to polypeptides, defined through a consensus sequence, having a length from 10 to 80 amino-acid residues, and whose polypeptidic sequence comprises or consists of the consensus sequence P1(X | 2014-11-13 |
20140336120 | Compositions And Method For Treatment Of Ischemic Neuronal Reperfusion Injury - A method and composition for the treatment of ischemic neuronal reperfusion injury are provided. The composition can include a compound which is a combination of dantrolene and a residue of FMOC-valine. This composition can be used to provide a faster and higher CNS penetration than heretofore experienced with dantrolene. In another form, dantrolene may be formulated as a pro-drug, a pro-pro-drug and the like. | 2014-11-13 |
20140336121 | FACTOR H FOR TREATMENT OF RHEUMATOID ARTHRITIS - The present invention provides a method for preventing or inhibiting allograft rejection by a recipient of that allograft by treating the recipient with a composition comprising Factor H (FH). The invention also encompasses methods in which the recipient is also administered one or more immunosuppressants in addition to the Factor H. | 2014-11-13 |
20140336122 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE - The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content. | 2014-11-13 |
20140336123 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof - This application describes a family of compounds acting as β-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases. | 2014-11-13 |
20140336124 | Compositions for Regenerating Defective or Absent Myocardium - Injectable collagen based graft compositions and grafts formed from the compositions for tissue regeneration. The compositions and grafts further include a glycosaminoglycan (GAG) to control matrix formation and remodeling. | 2014-11-13 |
20140336125 | METHODS FOR IMPROVING THE BIOACTIVITY CHARACTERISTICS OF A SURFACE AND OBJECTS WITH SURFACES IMPROVED THEREBY - A method for improving bioactivity and/or biodegradation time of a collagen surgical implant and collagen surgical implants having such improved properties. A gas-cluster ion-beam (GCIB) is formed in a reduced-pressure chamber, a collagen surgical implant is introduced into the reduced-pressure chamber, and at least a first portion of the surface of said collagen surgical implant is irradiated with a GCIB-derived beam. | 2014-11-13 |
20140336126 | OPTINEURIN-DERIVED POLYPEPTIDES, THEIR NUCLEIC ACIDS AND USES THEREOF - The invention relates to Optineurin-derived polypeptide(s) consisting of a polypeptidic sequence disclosed in SEQ ID no2, which represents the portion of the wild-type human Optineurin protein sequence from its amino-acid residue 131 to its amino-acid residue 297, or having a polypeptidic sequence encompassing the polypeptidic sequence disclosed in SEQ ID no2, or having a polypeptidic sequence derived from the polypeptidic sequence disclosed in SEQ ID no2 to the exclusion of the wild-type Optineurin protein. The polypeptide(s) of the invention retain one, any combination of two, or three of the following functional properties: the capacity to bind Rab8 protein, when the latter are associated with the Golgi apparatus of a cell, the capacity to bind MYPT1 protein, when said protein is engaged in a Myosin-Phosphatase (MP) complex, the capacity to be phosphorylated by Plk1. The invention also relates to nucleic acid molecule(s) encoding such polypeptide(s), vector(s) and method(s) of production thereof, alteration(s). | 2014-11-13 |
20140336127 | Stabilized Peptide Helices For Inhibiting Dimerization Of Chemokine C Motif Receptor 2 (CCR2) - Peptide helices stabilized by backbone cyclization which are capable of inhibiting dimerization of the Chemokine (C-C motif) receptor 2 (CCR2), as well as pharmaceutical compositions including such backbone cyclized peptide helices. Use of pharmaceutical compositions and peptide helices in treatment of Multiple Sclerosis (MS) and other diseases associated with CCR2 activation. | 2014-11-13 |
20140336128 | GIGAXONIN FUSION PROTEIN AND METHODS FOR TREATING GIANT AXONAL NEUROPATHY - The present disclosure relates generally to fusion proteins including gigaxonin coupled to a cell penetrant peptide. These fusion proteins can be used to treat GAN in a subject in need thereof. Administration of the fusion proteins allows for control of at least one of Galectin-1 (GAL-1) levels and phosphorylated vimentin protein levels, thereby mediating aggregation of vimentin and the formation of vimentin-free zones in cells. | 2014-11-13 |
20140336129 | Targeting the EGFR-SGLT1 Interaction for Cancer Therapy - A compound can destabilize a binding interaction between an epidermal growth factor receptor (EGFR) and a sodium/glucose co-transporter 1 (SGLT 1). In one embodiment, the compound is a peptide derived from the interacting domain of EGFR. In another embodiment, the peptide is administered to a patient to treat cancer. | 2014-11-13 |
20140336130 | TARGETING EN2, PAX2, AND/OR DEFB1 FOR TREATMENT OF PROSTATE CONDITIONS - The present invention relates to the compositions and use of compositions for treating a prostate condition in a subject. The use of composition comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity. | 2014-11-13 |
20140336131 | METHODS FOR TREATING INFLAMMATION, AUTOIMMUNE DISORDERS AND PAIN - Disclosed herein are methods of treating, reducing, or preventing a disease such as oral mucositis, gastric mucositis, or inflammatory fibrosis, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein. | 2014-11-13 |
20140336132 | ROMIDEPSIN SOLID FORMS AND USES THEREOF - The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I. | 2014-11-13 |
20140336133 | METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE - Disclosed herein are methods and compositions for treating or preventing Huntington's Disease. | 2014-11-13 |
20140336134 | IAP BIR Domain Binding Compounds - A compound of Formula I | 2014-11-13 |
20140336135 | NOVEL USE OF RHODODENDRIN - The present invention relates to a novel use of rhododendrin, and more particularly to a composition for antioxidant purposes or for the prevention or treatment of hyperproliferative skin disorders, which comprises rhododendrin as an active ingredient; and a method for inhibiting reactive oxygen species or for preventing and treating a hyperproliferative skin disorder, which comprises administering an effective amount of rhododendrin to a subject in need thereof. Rhododendrin is not cytotoxic and has an excellent effect of eliminating a large amount of reactive oxygen species (ROS) generated by TNF-α/IFN-γ or UV light, and thus is effectively used to prepare an antioxidant cosmetic composition or an antioxidant food composition. In addition, rhododendrin has the effect of inhibiting skin cell hyperproliferation and has an excellent effect of inhibiting a hyperproliferative skin disorder or skin hyperkeratinization mediated by Toll-like receptors (TLRs) in various skin diseases, particularly psoriasis. | 2014-11-13 |
20140336136 | Carboxylated Stilbenes For Activating AMPK And Sirtuins - The present invention relates to the use of certain stilbene derivatives for cosmetic and dermatological applications, in particular prevention and/or treatment of skin aging, as well as to cosmetic and dermatological compositions containing such stilbene derivatives. | 2014-11-13 |
20140336137 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF - The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer. | 2014-11-13 |
20140336138 | COMPOSITIONS AND METHODS FOR SCREENING AND TREATMENT OF STURGE-WEBER SYNDROME, KLIPPEL-TRENAUNAY-WEBER SYNDROME, AND PORT-WINE STAINS (PWSS) - Compositions and methods for treatment of Sturge-Weber Syndrome, Klippel-Trenaunay-Weber Syndrome, Port-Wine Stains and related neurocutaneous disorders are provided. Cell lines having the somatic mutation GNAQ p.Arg183Gln amino acid substitution, which was found to be the cause of port-wine stains (prevalence 1 in 300) and Sturge-Weber syndrome are also provided. Compositions and methods for treatment of uveal melanoma are also provided herein. Methods of screening novel compounds and compositions useful in increasing RGS2 and/or RGS4 expression and function in vitro, and for treatment of Sturge-Weber Syndrome, Klippel-Trenaunay-Weber Syndrome, Port-Wine Stains and related neurocutaneous disorders are provided are also provided. | 2014-11-13 |
20140336139 | TOPICAL APPLICATION OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS/AFFLICTIONS - Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin. | 2014-11-13 |
20140336140 | METHODS FOR PROVIDING SIALYLATED OLIGOSACCHARIDES - The invention relates to a method for providing analogs of human milk oligosaccharides (HMO), in particular oligosaccharides containing terminal sialic acid. The method comprises the steps of: a) providing a source of non-digestible galactooligosaccharides (GOS) containing at least two terminally bonded β-linked galactose residues; b) providing a sialic acid donor having (α2-3)-sialylated O-glycans; c) contacting said GOS with said sialic acid donor in the presence of an enzyme having trans-sialidase activity in an enzyme reaction mixture; and d) isolating from said enzyme reaction mixture a fraction comprising at least 20 percent by weight of disialylated galactooligosaccharides (di-Sia-GOS) based on the dry matter. | 2014-11-13 |
20140336141 | MAO-B INHIBITORS DERIVED FROM THE ONE-CARBON CYCLE - The invention exploits the elucidation of a connection between the S-adenosylmethionine one-carbon cycle and MAO-B levels and describes drug efficacy testing methods and the use of compounds of the S-adenosylmethionine one-carbon cycle as MAO-B inhibitors in disease prevention and treatment. | 2014-11-13 |
20140336142 | Method For Treatment Of Macular Degeneration By Modulating P2Y12 or P2X7 Receptors - Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pH | 2014-11-13 |
20140336143 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION - A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient. | 2014-11-13 |
20140336144 | External Preparation Containing NSAIDS And Method For Producing The External Preparation - Disclosed is an external preparation containing nonsteroidal anti-inflammatory drugs (NSAIDs), which is suppressed in cytotoxicity induced by the NSAIDs. Also disclosed is a method for producing the external preparation. The present invention is based on the finding that skin disorders induced by nonsteroidal anti-inflammatory drugs (NSAIDs) can be suppressed when the NSAIDs form intermolecular compounds together with trehalose, which is an example of disaccharides. A disaccharide other than trehalose may be used therefor. | 2014-11-13 |
20140336145 | COMPOSITIONS AND METHODS FOR TREATING OCULOPHARYNGEAL MUSCULAR DYSTROPHY - The present invention provides intravenous compositions of trehalose for the treatment of signs and symptoms of oculopharyngeal muscular dystrophy (OPMD). | 2014-11-13 |
20140336146 | Novel galectoside inhibitors of galectins - The present invention relates to novel compounds prepared from readily accessible 3-O-propargyl-D-galactopyranoside derivatives and having an effect as i.a., galectin inhibitors, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to ligands in a mammal, wherein said galectin is preferably a galectin-3. The novel compounds are defined by the general formula (I). | 2014-11-13 |
20140336147 | HEMOSTATIC AGENTS AND METHODS OF USE - Modified chitosan hemostatic agents include reverse micelles ( | 2014-11-13 |
20140336148 | COMBINATIONS OF DIACEREIN AND NON-STEROIDAL INFLAMMATION DRUGS - The present invention relates to novel pharmaceutical combinations with synergistic action of diacerein or a pharmaceutically acceptable salt of diacerein and non-steroidal inflammatory drugs, having analgesic, anti-inflammatory, antipyretic, and osteoarthritis-treating activities. | 2014-11-13 |
20140336149 | PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL-CYCLODEXTRIN INCLUSION COMPLEX AND ITS PREPARING PROCESS - A docetaxel inclusion complex having improved water-solubility (up to 5 mg/ml) and stability (stability constant Ka=2056M | 2014-11-13 |
20140336150 | Administration of Karenitecin for the Treatment of Platinum and/or Taxane Chemotherapy-Resistant or -Refractory Advanced Ovarian Cancer - The present invention discloses and claims methods and compositions for the treatment of subjects having advanced ovarian cancer, including platinum and/or taxane chemotherapy resistant or refractory sub-populations, with the administration to the subject having advanced ovarian cancer of the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2′-trimethylsilyl)ethyl]-20(S) camptothecin) in an amount sufficient to provide a therapeutic benefit. The administration of Karenitecin by intravenous (i.v.) and/or oral methodologies are also disclosed and claimed. Methods for the administration of Karenitecin to increase Progression Free Survival (PFS) are also disclosed and claimed herein. | 2014-11-13 |
20140336151 | Silicon-Containing Fumaric Acid Esters - The present invention is directed to silicon-containing fumaric acid esters of the Formulae I-IV. The silicon-containing fumaric acid esters of Formulae I-IV are useful in transplantation medicine and for the treatment of autoimmune diseases and autoimmune-related diseases. (I), (II), (III) & (IV) | 2014-11-13 |
20140336152 | COMPOSITION FOR WET WIPES THAT ENHANCES THE EFFICACY OF CLEANSING WHILE BEING GENTLE TO THE SKIN - The present invention describes an oil-in-water emulsion composition for wet-wipes delivering an improved body cleansing performance while providing a gentle and smooth feeling to the user. | 2014-11-13 |
20140336153 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS - The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particularly FabI inhibitors. Formula (I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage anti-bacterial agents, more particularly FabI inhibitors. The present invention also provides methods for synthesizing and administering the FabI inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. | 2014-11-13 |
20140336154 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2014-11-13 |
20140336155 | Active Substance Combination Based on Trifluorobutinyl Compounds and Exhibiting Nematicidal and Insecticidal Properties - The invention relates to novel active substance combinations consisting of heterocyclic trifluorobutenylen of formula (1), wherein X is halogen and n is 0, 1 or 2, and of known insecticide substances. Said novel active substance combinations are suitable for fighting harmful pests like insects and nematodes. | 2014-11-13 |
20140336156 | ANTIBODIES TO 25-HYDROXYVITAMIN D2 AND D3 AND USES THEREOF - Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. The methods involve the detection or quantification of 25-hydroxyvitamin D2 and D3. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25-hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample. | 2014-11-13 |
20140336157 | METHODS AND COMPOSITIONS FOR TREATING CANCER - Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C | 2014-11-13 |
20140336158 | NK1 ANTAGONISTS | 2014-11-13 |
20140336159 | METHODS FOR TREATING AND DIAGNOSING RESPIRATORY TRACT INFECTIONS - Described are methods of preventing, treating and diagnosing of a subject having a condition, such as, an inflammation or infection of the respiratory tract. Methods of treatment and prevention include administration of effective amounts of calcium salt formulations to a subject. Methods of diagnosing include the use of biomarkers and optionally the use of kits that can detect biomarkers. Further described are methods for modulating an immune response that include the modulation of Toll-like receptors. | 2014-11-13 |
20140336160 | NOVEL GLUCOCORTICOLD RECEPTOR AGONISTS - This invention relates to novel glucocorticoid receptor agonists of formula (I): | 2014-11-13 |
20140336161 | PHARMACEUTICAL FORMULATIONS CONTAINING CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION - The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester. | 2014-11-13 |
20140336162 | LOCALLY ADMINISTRATED LOW DOSES OF CORTICOSTEROIDS - This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot. | 2014-11-13 |
20140336163 | METHODS OF PRESERVING INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLODEXTRIN AND A HYDROPHOBIC DRUG - The invention relates to injectable pharmaceutical compositions, methods of use and formulation, wherein the compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products. | 2014-11-13 |
20140336164 | BIODEGRADABLE NON-OPHTHALMIC IMPLANTS AND RELATED METHODS - Biodegradable non-ophthalmic implants include one or more agents dispersed within a biodegradable polymer component. The implants release the agents from the biodegradable polymer component to a target site of a patient as the implant degrades. The agents provided in the implants can be therapeutic agents or diagnostic agents and are useful in medical treatments of non-ocular regions of a patient. | 2014-11-13 |
20140336165 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND - Provided is a compound having a D-amino acid oxidase (DAAO) inhibitory action, and useful as, for example, a prophylaxis and/or therapeutic agent for schizophrenia or neuropathic pain. | 2014-11-13 |
20140336166 | NOVEL PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The invention relates to PI3K inhibitors of the formula (I) • in which all of the variables are as defined in the specification, to their preparation, to their medical use, in particular to their use in the treatment of cancer and neurodegenerative disorders, and to medicaments comprising them. | 2014-11-13 |
20140336167 | NAMPT INHIBITORS - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. | 2014-11-13 |
20140336168 | NAMPT INHIBITORS - Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. | 2014-11-13 |
20140336169 | IMIDAZOPYRAZINE SYK INHIBITORS - Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample. | 2014-11-13 |
20140336170 | INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS - The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X. | 2014-11-13 |
20140336171 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2014-11-13 |
20140336172 | Novel 2H-Indazoles as EP2 Receptor Antagonists - The present invention relates to novel 2H-indazoles of the general formula (I), methods for the preparation thereof and the use thereof for the production of pharmaceutical agents for the treatment of diseases and indications which are linked with the EP | 2014-11-13 |
20140336173 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS - This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives of formula (I) wherein R | 2014-11-13 |
20140336174 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease - A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor. | 2014-11-13 |
20140336175 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES - The present invention relates to compounds of formula (I): | 2014-11-13 |
20140336176 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS - The present invention provides, in part, compounds of Formula I: | 2014-11-13 |
20140336177 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - The present invention provides compounds of Formula I | 2014-11-13 |
20140336178 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES - The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another. | 2014-11-13 |
20140336179 | ACETONE SOLVATE OF IVABRADINE HYDROCHLORIDE - The present invention relates to a novel solvate of ivabradine hydrochloride, a process of its preparation and its use for the preparation of specific polymorphic forms of ivabradine hydrochloride. | 2014-11-13 |
20140336180 | COMBINATION OF MEK INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE - The present invention relates to methods for the treatment of proliferative disorders. In particular, the invention provides methods for treatment of proliferative disorders by administering a MEK inhibitor in combination with a selective inhibitor of Aurora A kinase. | 2014-11-13 |
20140336181 | Use of polymorphisms for identifying individuals at risk of developing autism - The present invention relates to nucleic-acid based diagnostics and the use of such diagnostics for the diagnosis of developmental disorders. Novel methods of assessing individuals for the risk of developing autism through the identification of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene alone or in combination with other genes associated with methylation pathways are identified. Methods of identifying those individuals that are at increased and/or decreased risk for developing autism are provided. | 2014-11-13 |